PEDIATRICS Vol. 103 No. 6 June 1999, pp. 1145-1149
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
Received Feb 22, 1999; accepted Mar 25, 1999.
,
From the Departments of * Oral and Maxillofacial Surgery and
Pediatrics, Massachusetts General Hospital, Boston, Massachusetts;
the § Department of Surgery, Children's Hospital, Boston,
Massachusetts; and the ¶ Division of Pediatric Hematology/Oncology,
Rhode Island Hospital, Providence Rhode Island.
We report a 5-year-old girl with a large rapidly growing giant cell tumor of the mandible that recurred 2 months after the first surgical excision and 3 months after a second resection. An angiogenic protein, (bFGF), was abnormally elevated in her urine. The patient was treated with interferon alfa-2a for 1 year because this agent inhibits angiogenesis by suppressing bFGF overexpression in infantile hemangiomas and in other human tumors. During this time the bone tumor regressed and disappeared, the urinary bFGF fell to normal levels, and the mandible regenerated. She has remained tumor-free and has been off therapy for 3 years at this writing.
This first successful use of interferon alfa-2a to treat a mandibular tumor in a child demonstrates: 1) low grade tumors that overexpress bFGF may respond to interferon alfa-2a, in a manner similar to life-threatening infantile hemangiomas; 2) antiangiogenic therapy, given without interruption for 1 year, was safe and effective in this patient; and 3) treatment may be continued for 1 year without the development of drug resistance.
Key words: interferon alfa-2a, basic fibroblast growth factor, angiogenesis, giant cell tumor of mandible.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Koster, J. H.J.M. van Krieken, M. A. MacKenzie, M. Schraders, G. F. Borm, J. A.W.M. van der Laak, W. Leenders, K. Hebeda, and J. M.M. Raemaekers Increased Vascularization Predicts Favorable Outcome in Follicular Lymphoma Clin. Cancer Res., January 1, 2005; 11(1): 154 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Wahl, T. L. Moser, and S. V. Pizzo Angiostatin and Anti-angiogenic Therapy in Human Disease Recent Prog. Horm. Res., January 1, 2004; 59(1): 73 - 104. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. O'Reilly Targeting Multiple Biological Pathways as a Strategy to Improve the Treatment of Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3309 - 3310. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Eder Jr, J. G. Supko, J. W. Clark, T. A. Puchalski, R. Garcia-Carbonero, D. P. Ryan, L. N. Shulman, J. Proper, M. Kirvan, B. Rattner, et al. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily J. Clin. Oncol., September 15, 2002; 20(18): 3772 - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Volpert, W. Luo, T.-J. Liu, V. T. Estrera, C. Logothetis, and S.-H. Lin Inhibition of Prostate Tumor Angiogenesis by the Tumor Suppressor CEACAM1 J. Biol. Chem., September 13, 2002; 277(38): 35696 - 35702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Folkman The Podium J. Law Med. Ethics, September 1, 2002; 30(3): 361 - 366. [PDF]
|
|
|
|
 |
|
 E. M. Hammond, A. J. Giaccia, T. Browder, J. Folkman, P. Hahnfeldt, J. Heymach, L. Hlatky, M. Kieran, M. S. Rogers, Robert. S. Kerbel, et al. Antiangiogenic Therapy and p53 Science, July 26, 2002; 297(5581): 471a - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kerbel Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results J. Clin. Oncol., September 15, 2001; 19(90001): 45s - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Murphey, G. C. Nomikos, D. J. Flemming, F. H. Gannon, H. T. Temple, and M. J. Kransdorf Imaging of Giant Cell Tumor and Giant Cell Reparative Granuloma of Bone: Radiologic-Pathologic Correlation RadioGraphics, September 1, 2001; 21(5): 1283 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Weissleder and U. Mahmood Molecular Imaging Radiology, May 1, 2001; 219(2): 316 - 333. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. L. Yu, J. W. Rak, P. Carmeliet, A. Nagy, R. S. Kerbel, and B. L. Coomber Heterogeneous Vascular Dependence of Tumor Cell Populations Am. J. Pathol., April 1, 2001; 158(4): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Gordon, K. Margolin, M. Talpaz, G. W. Sledge Jr, E. Holmgren, R. Benjamin, S. Stalter, S. Shak, and D. C. Adelman Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer J. Clin. Oncol., February 1, 2001; 19(3): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. STUEBIGER, I. KOETTER, and M. ZIERHUT Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet's disease Br J Ophthalmol, December 1, 2000; 84(12): 1432g - 1432. [Full Text]
|
|
|
|
 |
|
 R. S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis, March 1, 2000; 21(3): 505 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Slaton, P. Perrotte, K. Inoue, C. P. N. Dinney, and I. J. Fidler Interferon-{{alpha}}-mediated Down-Regulation of Angiogenesis-related Genes and Therapy of Bladder Cancer Are Dependent on Optimization of Biological Dose and Schedule Clin. Cancer Res., October 1, 1999; 5(10): 2726 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Dickerman Interferon and Giant Cell Tumors Pediatrics, June 1, 1999; 103(6): 1282 - 1283. [Full Text]
|
|
